Trade Anatomy Portfolio
+.73% Month End | +33.24% YTD
4 long | 2 buys | 1 sell
The S&P 500 has now made it 5 up weeks in a row, finishing October 2015 in impressive fashion. The index was able to flip the initial trailing yellow line, which as of late, has marked the resumption of the uptrend. If all goes well over the next month or so, the main trailing stop (blue line) should likewise resume its uptrend. The key ingredient still missing is an increase of stocks passing the trading screens. Over the last 3 weeks, the list as barely budged. During the prior two trend reversals, the lists populated quickly with a healthy number of candidates, making the trading picture much clearer.
For the last week of October, there were 2 buys and 1 sell for the portfolio. On the 26th and 28th, LYTS was added to the Trade Anatomy portfolio. The combination of trades places the average initial entry at 10.59 utilizing 7.72% of our trading capital.
On the 28th, GLD was also initiated at 113.09 with a 10% total position. Initially it appeared that GLD was poised to break its current downtrend. However, by the afternoon, GLD had reversed all of its gains, making it clear that GLD was not ready to break through resistance. The position was sold at 111.40 and a small loss was taken. GLD negatively impacted the total portfolio by .15%.
With 4 open positions, the Trade Anatomy portfolio is 25% invested. The current prices of our open positions still remain relatively close to their initial entry points. A little added price appreciation over the next few weeks would go along way in terms of breathing room from our initial stops.
Although the stock screens have not shown a marked increase over the last several weeks, the stocks passing the screens have developed more constructive trading patterns. It only takes a few strong stocks to make a difference to the portfolio's value. Possibly a few of these will present themselves through the screening process. Below are a few names currently on the watchlist.